| 000 | 01888 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250517172254.0 | ||
| 264 | 0 | _c20171128 | |
| 008 | 201711s 0 0 eng d | ||
| 022 | _a1528-0020 | ||
| 024 | 7 |
_a10.1182/blood-2017-05-786137 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMalard, Florent | |
| 245 | 0 | 0 |
_aRituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. _h[electronic resource] |
| 260 |
_bBlood _c11 2017 |
||
| 300 |
_a2186-2195 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdrenal Cortex Hormones _xtherapeutic use |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aB-Lymphocytes _xpathology |
| 650 | 0 | 4 | _aB7-H1 Antigen |
| 650 | 0 | 4 | _aChronic Disease |
| 650 | 0 | 4 |
_aCyclosporine _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLymphocyte Count |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aRituximab _xadministration & dosage |
| 650 | 0 | 4 |
_aStem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aT-Lymphocytes, Helper-Inducer _xcytology |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aLabopin, Myriam | |
| 700 | 1 | _aYakoub-Agha, Ibrahim | |
| 700 | 1 | _aChantepie, Sylvain | |
| 700 | 1 | _aGuillaume, Thierry | |
| 700 | 1 | _aBlaise, Didier | |
| 700 | 1 | _aTabrizi, Reza | |
| 700 | 1 | _aMagro, Leonardo | |
| 700 | 1 | _aVanhove, Bernard | |
| 700 | 1 | _aBlancho, Gilles | |
| 700 | 1 | _aMoreau, Philippe | |
| 700 | 1 | _aGaugler, Béatrice | |
| 700 | 1 | _aChevallier, Patrice | |
| 700 | 1 | _aMohty, Mohamad | |
| 773 | 0 |
_tBlood _gvol. 130 _gno. 20 _gp. 2186-2195 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1182/blood-2017-05-786137 _zAvailable from publisher's website |
| 999 |
_c27521019 _d27521019 |
||